Search

Author/Creator Morrow, Michelle

1. 715 FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action. (10th December 2020)

Authors:
Morrow, Michelle; Faroudi, Mustapha; Chakraborty, Krishnendu; Liao, Wenjia; Winnewisser, Julia; Seal, Claire; Gliddon, Daniel; Brewis, Neil
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A428
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 715 FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action. (9th November 2020)

Authors:
Morrow, Michelle; Faroudi, Mustapha; Chakraborty, Krishnendu; Liao, Wenjia; Winnewisser, Julia; Seal, Claire; Gliddon, Daniel; Brewis, Neil
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A757
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A mouse GITRl fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer. (4th November 2015)

Authors:
Leyland, Rebecca; Watkins, Amanda; Bamber, Lisa; Tigue, Natalie; Young, Lesley; Morrow, Michelle; Hammond, Scott; Wilkinson, Robert; Stewart, Ross
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A mouse GITRl fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer. Issue 2 (December 2015)

Authors:
Leyland, Rebecca; Watkins, Amanda; Bamber, Lisa; Tigue, Natalie; Young, Lesley; Morrow, Michelle; Hammond, Scott; Wilkinson, Robert; Stewart, Ross
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. Issue 1 (1st January 2021)

Authors:
Schofield, Darren J.; Percival-Alwyn, Jennifer; Rytelewski, Mateusz; Hood, John; Rothstein, Raymond; Wetzel, Leslie; McGlinchey, Kelly; Adjei, Grace; Watkins, Amanda; Machiesky, LeeAnn; Chen, Weimin; Andrews, John; Groves, Maria; Morrow, Michelle; Stewart, Ross A.; Leinster, Andrew; Wilkinson, Ro...
Journal:
MAbs
Issue:
Volume 13:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report. Issue 10 (6th October 2022)

Authors:
Kroloff, Maxwell J; Holz, Josefin-Beate; Stern, Omer; Shepherd, Christopher J; Morrow, Michelle; Kayitalire, Louis; Wong, Deborah J
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. (6th November 2014)

Authors:
Dovedi, Simon; Adlard, Amy; Lipowska-Bhalla, Grazyna; McKenna, Conor; Jones, Sherrie; Cheadle, Eleanor; Stratford, Ian; Poon, Edmund; Morrow, Michelle; Stewart, Ross; Jones, Hazel; Wilkinson, Robert W; Honeychurch, Jamie; Illidge, Tim
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗